BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a biopharmaceutical company focused on developing treatments for genetic conditions. The company is set to release its quarterly earnings on February 24, 2026. Wall Street anticipates an earnings per share (EPS) of -$0.75 and revenue of around $149.1 million. BBIO will also host a conference call to discuss these results and provide business updates.
BBIO's financial metrics reveal some challenges. The company has a negative price-to-earnings (P/E) ratio of -16.23, indicating it is not currently profitable. This is further emphasized by an earnings yield of -6.16%. Despite these figures, BBIO's price-to-sales ratio of 37 suggests investors are optimistic about its future sales potential.
The enterprise value to sales ratio for BBIO is approximately 40.44, reflecting its valuation relative to revenue. However, the enterprise value to operating cash flow ratio is negative at -24.46, indicating difficulties in generating positive cash flow from operations. This could be a concern for investors looking for immediate returns.
BBIO's debt-to-equity ratio is negative at -0.96, suggesting the company has more liabilities than equity. This could be a risk factor, but the strong current ratio of 3.88 indicates BBIO has sufficient liquidity to cover short-term obligations. This liquidity is crucial for the company to continue its operations and invest in its development programs.
Investors and interested parties can access the live webcast of BBIO's presentation through the company's website. A replay will be available for 30 days, providing an opportunity to review the company's financial results and updates on its programs.
